NCT05607108View on ClinicalTrials.gov

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Squamous Cell Lung Cancer
Interventions
DRUG

ZEN003694

ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ), Commack

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities, Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

Sponsors

Collaborators (1)

Zenith Epigenetics
All Listed Sponsors
collaborator

Zenith Epigenetics

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER